LUDLUM KEN
Known title: DirectorCIK: 0001255825
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Competitors Tempus and Natera draw market attention. Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.
Transaction History
| IRIX | ▲ Buy | Grant | 39,267 | $75K | 6/14/2023 | View on chart |
| IRIX | ▲ Buy | Grant | 27,472 | $0 | 6/15/2022 | View on chart |
| PSNL | ▲ Buy | Grant | 10,770 | $0 | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
IRIX Completes Move of Manufacturing Facility to San Jose
Iridex has finished moving its manufacturing operations to a new facility in San Jose, California. The relocation may affect the company's production schedule as it adjusts to the new site. Investors may watch how the transition influences operating costs and supply chain efficiency.
IRIX Completes Move of Manufacturing Facility to San Jose. Iridex has finished moving its manufacturing operations to a new facility in San Jose, California. The relocation may affect the company's production schedule as it adjusts to the new site. Investors may watch how the transition influences operating costs and supply chain efficiency.